Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 rats

Oncology Reports

Volumn 30, Issue 2, 2013, Pages 952-960

  Janakiram, Naveena B ^a   Mohammed, Altaf ^a   Ravillah, Durgadevi ^a   Choi, Chang In ^a   Zhang, Yuting ^a   Desai, Dhimant ^b   Amin, Shantu ^b   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Aberrant crypt foci; Chemoprevention; Colon cancer; iNOS inhibitor; Selenium

Indexed keywords

1,4 PHENYLENEBIS(1,2 ETHANEDIYL)BISISOSELENOUREA; 1,4 PHENYLENEBIS(1,2 ETHANEDIYL)BISISOTHIOUREA; ANTINEOPLASTIC AGENT; CYCLIN D1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; SELENIUM DERIVATIVE; UNCLASSIFIED DRUG;

ABERRANT CRYPT FOCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN CACO 2; COLON CARCINOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ABERRANT CRYPT FOCI; ANIMALS; APOPTOSIS; AZOXYMETHANE; CACO-2 CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOPREVENTION; COLONIC NEOPLASMS; CYCLIN D1; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, INBRED F344; SELENIUM COMPOUNDS; THIOUREA;

EID: 84879654253     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2483     Document Type: Article

References (56)

1. American Cancer Society. Colorectal cancer key statistics. Available at: http://www.cancer.org/Cancer/ColonandRectumCancer/DetailedGuidecolorectal- cancer-key-statistics.
2. Jackson JR, Seed MP, Kircher CH, Willoughby DA and Winkler JD: The codependence of angiogenesis and chronic inflammation. FASEB J 11: 457-465, 1997. (Pubitemid 27259987)
3. Phoa N and Epe B: Influence of nitric oxide on the generation and repair of oxidative DNA damage in mammalian cells. Carcinogenesis 23: 469-475, 2002. (Pubitemid 34257627)
4. Jaiswal M, LaRusso NF, Burgart LJ and Gores GJ: Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60: 184-190, 2000. (Pubitemid 30058750)
5. Moore MA: Cytokine and chemokine networks influencing stem cell proliferation, differentiation, and marrow homing. J Cell Biochem 38: 29-38, 2002.
6. Nakajima N, Kuwayama H, Ito Y, Iwasaki A and Arakawa Y: Helicobacter pylori, neutrophils, interleukins, and gastric epithelial proliferation. J Clin Gastroenterol 25: S198-S202, 1997. (Pubitemid 28117028)
7. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994. (Pubitemid 24294584)
8. Rhodes JM and Campbell BJ: Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med 8: 10-16, 2002. (Pubitemid 34044673)
9. Keshavarzian A, Fusunyan RD, Jacyno M, Winship D, MacDermott RP and Sanderson IR: Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon. Am J Gastroenterol 94: 704-712, 1999. (Pubitemid 29124870)
10. Nusrat A, Sitaraman SV and Neish A: Interaction of bacteria and bacterial toxins with intestinal epithelial cells. Curr Gastroenterol Rep 3: 392-398, 2001.
11. Weiss HA and Forman D: Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence. Scand J Gastroenterol 220: 137-141, 1996. (Pubitemid 26338399)
12. Jenkins DC, Charles IG, Thomsen LL, et al: Roles of nitric oxide in tumour growth. Proc Natl Acad Sci USA 92: 4392-4396, 1995.
13. Ambs S, Merriam WG, Bennett WP, et al: Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumour angiogenesis and colon cancer progression. Cancer Res 58: 334-341, 1998. (Pubitemid 28047076)
14. Jobin C, Haskill S, Mayer L, Panja A and Sartor RB: Evidence for altered regulation of I kappa B alpha degradation in human colonic cells. J Immunol 158: 226-234, 1997. (Pubitemid 127483860)
15. Knowles RG and Moncada S: Nitric oxide synthases in mammals. Biochem J 298: 249-258, 1994. (Pubitemid 24072462)
16. Forstermann U, Gath I, Schwarz P, Closs EI and Kleinert H: Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Biochem Pharmacol 50: 1321-1332, 1995.
17. Pana MH and Ho CT: Chemopreventive effects of natural dietary compounds on cancer development. Chem Soc Rev 37: 2558-2574, 2008.
18. Rao CV, Kawamori T, Hamid R and Reddy BS: Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 2: 641-644, 1999. (Pubitemid 29151301)
19. Briske-Anderson MJ, Finley JW and Newman SM: The influence of culture time and passage number on the morphological and physiological development of CaCo2 cells. Proc Soc Exp Biol Med 214: 248-257, 1997.
20. Huang Y, Li N, Liboni K and Neu J: Glutamine decreases lipopolysaccharide-induced IL-8 production in Caco-2 cells through a non-NF-kappaB p50 mechanism. Cytokine 22: 77-83, 2003. (Pubitemid 36808765)
21. Chittezhath M, Deep G, Singh RP, Agarwal C and Agarwal R: Silibinin inhibits cytokine-induced STATs, MAPKs, NF-κB and AP-1 activation, and down-regulates HIF-1α and iNOS in human lung carcinoma A549 cells. Mol Cancer Ther 7: 1817-1826, 2008.
22. Bird RP: Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 37: 147-151, 1987.
23. Janakiram NB, Mohammed A, Zhang Y, Choi CI, Woodward C, Collin P, Steele VE and Rao CV: Chemopreventive effects of Frondanol A5, a Cucumaria frondosa extract, against rat colon carcinogenesis and inhibition of human colon cancer cell growth. Cancer Prev Res 3: 82-91, 2010.
24. Arthur JR, McKenzie RC and Beckett GJ: Selenium in the immune system. J. Nutr 133: S1457-S1459, 2003.
25. Chung CY, Madhunapantula SV, Desai D, Amin S and Robertson GP: Melanoma prevention using topical PBI-Se. Cancer Prev Res 4: 935-948, 2011.
26. Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36: 131-149, 2003. (Pubitemid 36808270)
27. Fusunyan RD, Quinn JJ, Fujimoto M, MacDermott RP and Sanderson IR: Butyrate switches the pattern of chemokine secretion by intestinal epithelial cells through histone acetylation. Mol Med 5: 631-640, 1999. (Pubitemid 32936953)
28. Ogle CK, Guo XL, Hasselgren PO, Ogle JD and Alexander JW: The gut as a source of inflammatory cytokines after stimulation with endotoxin. Eur J Surg 163: 45-51, 1997. (Pubitemid 27062351)
29. Haller D, Bode C, Hammes WP, Pfeifer AMA, Schiffrin EJ and Blum S: Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 47: 79-87, 2000. (Pubitemid 30430415)
30. Kibriya MG, Jasmine F, Argos M, Verret WJ, Rakibuz-Zaman M, Ahmed A, Parvez F and Ahsan H: Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett 169: 162-176, 2007. (Pubitemid 46275321)
31. Terui Y, Ikeda M, Tomizuka H, et al: Identification of a novel apoptosis-inducing factor derived from leukemic cells: endothelial interleukin-8, but not monocyte-derived, induces apoptosis in leukemic cells. Biochem Biophys Res Commun 243: 407-411, 1998. (Pubitemid 28414038)
32. Terui Y, Ikeda M, Tomizuka H, et al: Activated endothelial cells induce apoptosis in leukemic cells by endothelial interleukin-8. Blood 92: 2672-2680, 1998. (Pubitemid 28469078)
33. Hoffmann E, Dittrich-Breiholz O, Holtmann H and Kracht M: Multiple control of interleukin-8 gene expression. J Leukoc Biol 72: 847-855, 2002. (Pubitemid 35365158)
34. Garat C and Arend WP: Intracellular IL-1Ra type 1 inhibits IL-1-induced IL-6 and IL-8 production in Caco-2 intestinal epithelial cells through inhibition of p38 mitogen-activated protein kinase and NF-kappaB pathways. Cytokine 23: 31-40, 2003. (Pubitemid 36937198)
35. Lee Li-F, Hellendall RP, Wang Y, Stephen Haskill J, Mukaida N, Matsushima K and Ting JP: IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol 164: 2769-2775, 2000.
36. Molica S, Vitelli G, Levato D, Levato L, Datillo A and Gandolfo GM: Clinico-biological implications of increased serum levels of interleukin -8 in B cell chronic lymphocytic leukemia. Haematologica 84: 208-211, 1999. (Pubitemid 29476922)
37. Gartner R, Albrich W and Angstwurm MW: The effect of a selenium supplementation on the outcome of patients with severe systemic inflammation, burn, and trauma. Biofactors 14: 199-204, 2001. (Pubitemid 32848315)
38. Murata Y, Ishiguro Y, Itoh J, Munakata A and Yoshida Y: The role of pro-inflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. Gastroenterol Clin North Am J 30: 56-60, 1995.
39. Combs GF Jr and Gray WP: Chemopreventive agents: selenium. Pharmacol Ther 79: 179-192, 1998.
40. Russo MW, Murray SC, Wurzelmann JI, Woosley JT and Sandler RS: Plasma selenium levels and the risk of colorectal adenomas. Nutr Cancer 28: 125-129, 1997. (Pubitemid 27396198)
41. Patterson BH and Levander OA: Naturally occurring selenium compounds in cancer chemoprevention trials: a workshop summary. Cancer Epidemiol Biomarkers Prev 6: 63-69, 1997. (Pubitemid 27030429)
42. Knekt P, Marniemi J, Teppo L, Heliovaara M and Aromaa A: Is low selenium status a risk factor for lung cancer? Am J Epidemiol 148: 975-982, 1998. (Pubitemid 28533737)
43. Fleet JC: Dietary selenium repletion may reduce cancer incidence in people at high risk who live in areas with low soil selenium. Nutr Rev 55: 277-279, 1997.
44. Shamberger RJ: The genotoxicity of selenium. Mutat Res 154: 28-48, 1985.
45. Young KL and Lee PN: Intervention studies on cancer. Eur J Cancer Prev 8: 91-103, 1999.
46. Burguera JL, Burguera M, Gallignani M, Alarcon OM and Burgueera JA: Blood serum selenium in the province of Merida, Venezuela, related to sex, cancer incidence and soil selenium content. J Trace Elem Electrolytes Health Dis 4: 73-77, 1990. (Pubitemid 20251482)
47. Combs GF Jr, Clark LC and Turnbull BW: Reduction of cancer risk with an oral supplement of selenium. Biomed Environ Sci 10: 227-234, 1997. (Pubitemid 127472084)
48. Clark LC, Combs GF Jr, Turnbull BW, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. JAMA 276: 1957-1963, 1996. (Pubitemid 26427723)
49. Combs GF Jr, Clark LC and Turnbull BW: An analysis of cancer prevention by selenium. Biofactors 14: 153-159, 2001. (Pubitemid 32848310)
50. Combs GF Jr: Food system-based approaches to improving micronutrient nutrition: the case for selenium. Biofactors 12: 39-43, 2000.
51. Zimmerman MB and Kohrle J: The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health. Thyroid 12: 867-878, 2002.
52. Ryan-Harshman M and Aldoori W: The relevance of selenium to immunity, cancer and infectious/inflammatory diseases. Can J Diet Pract Res 66: 98-102, 2005. (Pubitemid 40825909)
53. Wood SM, Beckham C, Yosioka A, Darban H and Watson RR: Beta-carotene and selenium supplementation enhances immune response in aged humans. Integr Med 2: 85-92, 2000.
54. Baum MK, Miguez-Burbano MJ, Campa A and Shor-Posner G: Selenium and interleukins in persons infected with human immunodeficiency virus type 1. J Infect Dis 182: S69-S73, 2000.
55. Lippman SM, Klein EA, Goodman PJ, et al: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301: 39-51, 2009.
56. Whanger PD: Selenium and its relationship to cancer: an update. Br J Nutr 91: 11-28, 2004.